Arcutis Biotherapeutics: FDA To Review SNDA For Roflumilast Cream 0.15%
Arcutis Biotherapeutics, Inc. (ARQT) announced the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children down to age 6.